Clinical meaning
Cancer pain is a complex, multidimensional experience that affects 55-70% of patients undergoing active treatment and up to 90% of patients with advanced disease. Pain in cancer arises through several distinct pathophysiological mechanisms that often coexist in the same patient. Nociceptive pain results from activation of peripheral pain receptors (nociceptors) by tissue damage and can be somatic (arising from bone, muscle, skin, and connective tissue -- described as aching, throbbing, or pressure-like) or visceral (arising from internal organs -- described as deep, cramping, squeezing, or referred to distant sites). Neuropathic pain results from direct injury to peripheral or central nervous system structures by tumor invasion or compression of nerves, nerve plexuses, or the spinal cord; it is described as burning, shooting, tingling, or electric-shock-like sensations and often responds poorly to standard analgesics alone. Bone pain is the most common type of cancer pain, occurring when tumor cells metastasize to bone and activate osteoclast-mediated bone resorption through the RANK-RANKL pathway. The tumor microenvironment releases inflammatory mediators (prostaglandins, cytokines including TNF-alpha and interleukins, nerve growth factor) that sensitize peripheral nociceptors, lowering their activation threshold (peripheral sensitization). Repeated nociceptive input to the dorsal horn of the spinal cord leads to central sensitization, where neurons become hyperexcitable, amplifying pain signals through increased NMDA receptor activation and wind-up phenomenon. The World Health Organization (WHO) Pain Ladder provides a systematic framework for cancer pain management using three steps: Step 1 (mild pain, 1-3 on numeric rating scale) uses non-opioid analgesics (acetaminophen, NSAIDs) with or without adjuvants; Step 2 (moderate pain, 4-6) adds weak opioids (codeine, tramadol) or low-dose strong opioids; Step 3 (severe pain, 7-10) uses strong opioids (morphine, hydromorphone, fentanyl) with or without non-opioids and adjuvants. Breakthrough pain (BTP) is a transient exacerbation of pain that occurs despite adequate baseline (around-the-clock) analgesia, affecting 40-80% of cancer patients. BTP is classified as spontaneous (unpredictable), incident (triggered by activity, movement, or coughing), or end-of-dose failure (pain returning before the next scheduled dose). The breakthrough dose is typically calculated as 10-15% of the total 24-hour opioid dose, administered as an immediate-release formulation. Equianalgesic dosing is the concept of calculating equivalent doses when converting between different opioids or routes of administration; oral morphine 30 mg is the reference standard (equivalent to morphine 10 mg IV/SC, hydromorphone 6 mg oral, or oxycodone 20 mg oral). Understanding these conversion ratios is essential for safe opioid rotation.